A$15 billion Molecular Imaging Market IBX - sole ASX player

Harvey recently retired as vice president of medical affairs at Hologic, a world-leader in mammography and women’s health.She previously served as director of breast imaging at the Johns Hopkins School of Medicine and is co-founder of the non-profit organisation Cure Women’s Cancer.

Harvey said.“MagSense brings precision and specificity to breast cancer imaging,” she said.“The technology has the promise of fewer false alarms and fewer overlooked cancers.“Like a pregnancy test that is pink or blue, the MagSense technology could provide an accurate yes or no answer to MRI as to whether cancer is present, and thereby enable a more personalised treatment the woman will receive.“This innovative tool will transform cancer detection and care, starting with HER2+ breast cancer.”

Imagion Biosystems’ (ASX:IBX) chief business officer Ward Detwiler said IBX’s proceeds from the capital raise would help achieve key milestones in 2025, including prioritising phase II clinical studies of MagSense in its first indication of HER2+ breast cancer and advancing two additional pipeline products in prostate and ovarian cancers.

https://www.theaustralian.com.au/business/*/content/imagion-set-to-improve-cancer-detection-through-molecular-mri/news-story/7bf0719205b74130fe01ba8ea4b5f256?amp&nk=c755697ce7a32eed7600f4c65f5a979a-1738199589

The global molecular imaging market size was estimated at USD 8.45 billion in 2023 and is expected to grow at a CAGR of 4.52% from 2024 to 2030. Major factors contributing to the market growth include the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders, technological advancements, and rising investment in Research and Development (R&D). For instance, According to the America College of Radiology, The president's 2024 budget proposes a significant increase in discretionary funds for the National Cancer Institute (NCI), aiming for USD 716 million, which is USD 500 million more than the FY 2023 allocation. These funds are intended to support research, prevention, diagnosis, and treatment efforts, all of which depend heavily on radiology and imaging tools.

SP historical low @ today’s 1.6c, close to cash backing level
$3m funding received last month by new investors who had controlled 75% of the company—-management/efficiency will be improved
Siemens supports the research as always
directors paid $100k cash @ 2c per share last month
SP dropped from 16c to 1.6c - business activities no changes

at current SP level, it’s a buy for me